Launch week offerEnds in00h00m00s

annual Promonthly Pro

Yi-Chao Zheng

Zhengzhou University

China

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Immunology

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (4)

Ning Wang

Associate Professor

The University of Hong Kong

HONG KONG

View details

Piet Herdewijn

professor

KU Leuven

BELGIUM

View details

Guo-Liang Lu

Senior Research Fellow

University of Auckland

NEW ZEALAND

View details

Yan Li

Associate Professor

University of Auckland

NEW ZEALAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yi-Chao Zheng

Research Interests

Make your next move.

Explore related searches

Articles (20)

Multiple gastric cancer tissue proteomic identification predicts CLU as a biomarker for anti-PD-1 immunotherapy

Discovery of 1,3,5-triazine-based LSD1 inhibitors to activate immune response in gastric cancer

Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy

Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics

Identification of Novel Phenoxazine-Derived LSD1 Inhibitors Suppressing Gastric Cancer Stemness by β-Catenin Transcriptional Regulation

A dual-cell-targeting epigenetic nano-editor for reshaping the intratumoral T cell niche

Comparative analysis for optimal LSD1 inhibitors evaluation techniques:pros and cons

LSD1 engaged ERα activation orchestrates the formation of migrasomes to promote gastric cancer metastasis

The Exploration of Indole-Based LSD1-Targeted Inhibitors for Enhanced Immune Response in Gastric Cancer via the PD-L1/PD-1 Axis

The multifaceted role of post-translational modifications of LSD1 in cellular processes and disease pathogenesis

Unleashing the Power of Covalent Drugs for Protein Degradation.

Degraders in epigenetic therapy: PROTACs and beyond

Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.

Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer

Decoding CLU (Clusterin): Conquering cancer treatment resistance and immunological barriers.

Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy

CD155 as an emerging target in tumor immunotherapy.

USP7 as an emerging therapeutic target: A key regulator of protein homeostasis.

LSD1 in drug discovery: From biological function to clinical application.

Collaborators (4)

Ning Wang

Piet Herdewijn

Guo-Liang Lu

Yan Li

Make your next move.